Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling
Abstract Inflammatory Bowel Disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC), requires a combination of procedures and tests in diagnosis and discrimination. This study aimed to delineate specific serum metabolomic biomarkers that diagnose IBD and differentiate IBD subgroups. Ser...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-90160-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025011853656064 |
|---|---|
| author | Ji Eun Kim Dong Ho Suh Yu Jin Park Chi Hyuk Oh Shin Ju Oh Hyeji Kang Yosep Ji Young Jin Kim Weon Kim Eun Sung Jung Chang Kyun Lee |
| author_facet | Ji Eun Kim Dong Ho Suh Yu Jin Park Chi Hyuk Oh Shin Ju Oh Hyeji Kang Yosep Ji Young Jin Kim Weon Kim Eun Sung Jung Chang Kyun Lee |
| author_sort | Ji Eun Kim |
| collection | DOAJ |
| description | Abstract Inflammatory Bowel Disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC), requires a combination of procedures and tests in diagnosis and discrimination. This study aimed to delineate specific serum metabolomic biomarkers that diagnose IBD and differentiate IBD subgroups. Serum samples and clinical metadata of the participants, IBD patients and Normal Controls (NC), were collected. Untargeted and targeted metabolomic analyses by high-resolution mass spectrometry and multivariate statistical approaches were applied. Further, Receiver Operating Characteristic (ROC) curves, pathways, and network analyses were conducted. Distinct clustering separated IBD patients from the NC, although the CD and UC subgroups overlapped in the non-targeted profiling. Targeted metabolomics revealed elevated tryptophan and indole-3-acetic acid levels and reduced primary-to-secondary bile acid ratios in both CD and UC patients. The differences in specific tryptophan metabolites between CD and UC were identified. The ROC analysis underscored the discriminatory power of the biomarkers (AUC values: NC vs. CD = 0.9738; NC vs. UC = 0.9887; UC vs. CD = 0.7140). Pathway analysis revealed alterations in glycerolipid metabolism, markedly differentiating UC from CD. Network analysis correlated metabolomic markers with the clinical phenotypes of IBD. Serum metabolomic biomarkers can precisely identify IBD, discriminate IBD subtypes, and further reveal the phenotypes of IBD. |
| format | Article |
| id | doaj-art-fb628cbc00e147848c1d6bab69b4a08e |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-fb628cbc00e147848c1d6bab69b4a08e2025-08-20T03:00:58ZengNature PortfolioScientific Reports2045-23222025-02-0115111210.1038/s41598-025-90160-7Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profilingJi Eun Kim0Dong Ho Suh1Yu Jin Park2Chi Hyuk Oh3Shin Ju Oh4Hyeji Kang5Yosep Ji6Young Jin Kim7Weon Kim8Eun Sung Jung9Chang Kyun Lee10Department of Gastroenterology, Center for Crohn’s and Colitis, Kyung Hee University Hospital, Kyung Hee University College of MedicineHEM Pharma Inc.HEM Pharma Inc.Department of Gastroenterology, Center for Crohn’s and Colitis, Kyung Hee University Hospital, Kyung Hee University College of MedicineDepartment of Gastroenterology, Center for Crohn’s and Colitis, Kyung Hee University Hospital, Kyung Hee University College of MedicineHEM Pharma Inc.HEM Pharma Inc.Department of Biobank, Seoul Clinical Laboratories (SCL)Department of Cardiology, Kyung Hee University Hospital, Kyung Hee University College of MedicineHEM Pharma Inc.Department of Gastroenterology, Center for Crohn’s and Colitis, Kyung Hee University Hospital, Kyung Hee University College of MedicineAbstract Inflammatory Bowel Disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC), requires a combination of procedures and tests in diagnosis and discrimination. This study aimed to delineate specific serum metabolomic biomarkers that diagnose IBD and differentiate IBD subgroups. Serum samples and clinical metadata of the participants, IBD patients and Normal Controls (NC), were collected. Untargeted and targeted metabolomic analyses by high-resolution mass spectrometry and multivariate statistical approaches were applied. Further, Receiver Operating Characteristic (ROC) curves, pathways, and network analyses were conducted. Distinct clustering separated IBD patients from the NC, although the CD and UC subgroups overlapped in the non-targeted profiling. Targeted metabolomics revealed elevated tryptophan and indole-3-acetic acid levels and reduced primary-to-secondary bile acid ratios in both CD and UC patients. The differences in specific tryptophan metabolites between CD and UC were identified. The ROC analysis underscored the discriminatory power of the biomarkers (AUC values: NC vs. CD = 0.9738; NC vs. UC = 0.9887; UC vs. CD = 0.7140). Pathway analysis revealed alterations in glycerolipid metabolism, markedly differentiating UC from CD. Network analysis correlated metabolomic markers with the clinical phenotypes of IBD. Serum metabolomic biomarkers can precisely identify IBD, discriminate IBD subtypes, and further reveal the phenotypes of IBD.https://doi.org/10.1038/s41598-025-90160-7MetabolomicsBiomarkersHigh-resolution mass spectrometryDiagnosisInflammatory bowel disease |
| spellingShingle | Ji Eun Kim Dong Ho Suh Yu Jin Park Chi Hyuk Oh Shin Ju Oh Hyeji Kang Yosep Ji Young Jin Kim Weon Kim Eun Sung Jung Chang Kyun Lee Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling Scientific Reports Metabolomics Biomarkers High-resolution mass spectrometry Diagnosis Inflammatory bowel disease |
| title | Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling |
| title_full | Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling |
| title_fullStr | Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling |
| title_full_unstemmed | Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling |
| title_short | Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling |
| title_sort | identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling |
| topic | Metabolomics Biomarkers High-resolution mass spectrometry Diagnosis Inflammatory bowel disease |
| url | https://doi.org/10.1038/s41598-025-90160-7 |
| work_keys_str_mv | AT jieunkim identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT donghosuh identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT yujinpark identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT chihyukoh identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT shinjuoh identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT hyejikang identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT yosepji identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT youngjinkim identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT weonkim identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT eunsungjung identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling AT changkyunlee identifyingrobustbiomarkersforthediagnosisandsubtypedistinctionofinflammatoryboweldiseasethroughcomprehensiveserummetabolomicprofiling |